.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022206

« Back to Dashboard
NDA 022206 describes RAPAFLO, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the RAPAFLO profile page.

The generic ingredient in RAPAFLO is silodosin. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the silodosin profile page.

Summary for NDA: 022206

Tradename:
RAPAFLO
Applicant:
Allergan Sales Llc
Ingredient:
silodosin
Patents:1

Pharmacology for NDA: 022206

Mechanism of ActionAdrenergic alpha-Antagonists

Suppliers and Packaging for NDA: 022206

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RAPAFLO
silodosin
CAPSULE;ORAL 022206 NDA Actavis Pharma, Inc. 52544-151 52544-151-00 17937 CAPSULE in 1 DRUM (52544-151-00)
RAPAFLO
silodosin
CAPSULE;ORAL 022206 NDA Actavis Pharma, Inc. 52544-151 52544-151-19 90 CAPSULE in 1 BOTTLE, UNIT-DOSE (52544-151-19)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength4MG
Approval Date:Oct 8, 2008TE:RLD:Yes
Patent:5,387,603Patent Expiration:Dec 1, 2018Product Flag?YSubstance Flag?YDelist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength8MG
Approval Date:Oct 8, 2008TE:RLD:No
Patent:5,387,603Patent Expiration:Dec 1, 2018Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 022206

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 20085,403,847► subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 20085,403,847► subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 20085,780,485► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc